

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40
minutes
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source
(CS) field
NEWS 4 AUG 24 ENCOMPPLIT/ENCOMPPLIT2 reloaded and enhanced
NEWS 5 AUG 24 CA/Caplus enhanced with legal status information for
U.S. patents
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in
CAS REGISTRY
NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM
thesaurus
NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and
Taiwanese Content Expanded
NEWS 9 OCT 21 Derwent World Patents Index enhanced with human
translated claims for Chinese Applications and
Utility Models
NEWS 10 NOV 23 Addition of SCAN format to selected STN databases
NEWS 11 NOV 23 Annual Reload of IFI Databases
NEWS 12 DEC 01 FRFULL Content and Search Enhancements
NEWS 13 DEC 01 DGENE, USGENE, and PCTGEN: new percent identity
feature for sorting BLAST answer sets
NEWS 14 DEC 02 Derwent World Patent Index: Japanese FI-TERM
thesaurus added
NEWS 15 DEC 02 PCTGEN enhanced with patent family and legal status
display data from INPADOCDB
NEWS 16 DEC 02 USGENE: Enhanced coverage of bibliographic and
sequence information
NEWS 17 DEC 21 New Indicator Identifies Multiple Basic Patent
Records Containing Equivalent Chemical Indexing
in CA/Caplus
NEWS 18 JAN 12 Match STN Content and Features to Your Information
Needs, Quickly and Conveniently
NEWS 19 JAN 25 Annual Reload of MEDLINE database
NEWS 20 FEB 16 STN Express Maintenance Release, Version 8.4.2, Is
Now Available for Download
NEWS 21 FEB 16 Derwent World Patents Index (DWPI) Revises Indexing
of Author Abstracts
NEWS 22 FEB 16 New FASTA Display Formats Added to USGENE and PCTGEN
INPADOCDB and INPAFAMDB Enriched with New Content
and Features
NEWS 23 FEB 16 INSPEC Adding Its Own IPC codes and Author's E-mail
Addresses

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:25:44 ON 29 MAR 2010

FILE 'REGISTRY' ENTERED AT 10:26:11 ON 29 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAR 2010 HIGHEST RN 1214990-69-8
DICTIONARY FILE UPDATES: 28 MAR 2010 HIGHEST RN 1214990-69-8

New CAS Information Use Policies - enter HELP USAGETERMS for details



TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010

Please note that search-term pricing does apply when conducting Smart SELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www-cas.org/support/stndgen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\105958911atest.str




chain nodes :
11 13 14
ring nodes :
1 2 3 4 5 6 7 8 9 10 15 16 17 18 19 20
chain bonds :
3-13 9-11 13-14 14-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 15-16 15-20 16-17 17-18
18-19 19-20
exact/norm bonds :
3-13 5-7 6-10 7-8 8-9 9-10 9-11 13-14 14-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20
isolated ring systems :
containing 1 :

G1:N,CH

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR



G1 N,CH

Structure attributes must be viewed using STN Express query preparation.


=> s 11 sss full
FULL SEARCH INITIATED 10:26:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 79487 TO ITERATE

100.0% PROCESSED 79487 ITERATIONS 291 ANSWERS
SEARCH TIME: 00.00.01

L2 291 SEA SSS FUL L1

=> d scan



L2 291 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 2,3-Quinoxalinedione, 6-(3-fluorobenzoyl)-1,4-dihydro-
MF C15 H9 F N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>
Uploading C:\Program Files\STNEXP\Queries\10595891last.str




chain nodes :
11 13 14 24
ring nodes :
1 2 3 4 5 6 7 8 9 10 15 16 17 18 19 20
chain bonds :
3-13 8-24 9-11 13-14 14-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 15-16 15-20 16-17 17-18
18-19 19-20
exact/norm bonds :
3-13 5-7 8-24 13-14 14-15
exact bonds :
6-10 7-8 8-9 9-10 9-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20
isolated ring systems :
containing 1 :

G1:N,CH

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom
24:CLASS

L3 STRUCTURE UPLOADED

=> d 13
L3 HAS NO ANSWERS
L3 STR



G1 N,CH

Structure attributes must be viewed using STN Express query preparation.

=> s 13

SAMPLE SEARCH INITIATED 10:28:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 319 TO ITERATE

100.0% PROCESSED 319 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5309 TO 7451
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=> s 13 sss full

FULL SEARCH INITIATED 10:28:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6242 TO ITERATE

100.0% PROCESSED 6242 ITERATIONS
SEARCH TIME: 00.00.02

0 ANSWERS

L5 0 SEA SSS FUL L3

=> fil cap
COST IN U.S. DOLLARS
FULL ESTIMATED COST

| SINCE FILE ENTRY | TOTAL SESSION |
|------------------|---------------|
| 385.04 | 385.26 |

FILE 'CAPLUS' ENTERED AT 10:29:32 ON 29 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 29 Mar 2010 VOL 152 ISS 14
FILE LAST UPDATED: 28 Mar 2010 (20100328/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 12
L6 18 L2

=> s 12 and (pry<2004 or py<2004)
18 L2
4301790 PRY<2004
2405050 PY<2004
L7 15 L2 AND (PRY<2004 OR PY<2004)

=> d 1-15 ibib abs hitstr

L7 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:523430 CAPLUS
DOCUMENT NUMBER: 143:60003
TITLE: Preparation of 6-substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
INVENTOR(S): Mabire, Dominique Jean-Pierre; Guillemont, Jerome Emile Georges; Van Dun, Jacobus Alphonsus Josephus; Somers, Maria Victorina Francisca; Wouters, Walter Boudewijn Leopold
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|--------------|
| WO 2005054210 | A1 | 20050616 | WO 2004-EP13164 | 20041118 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, TG, UG, ZM, ZW,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR,
NE, SN, TD, TG | | | | |
| AU 2004295059 | A1 | 20050616 | AU 2004-295059 | 20041118 <-- |
| CA 2546657 | A1 | 20050616 | CA 2004-2546657 | 20041118 <-- |

| | | | | |
|---|--|---|------------------|----------------|
| EP 1709012 | A1 | 20061011 | EP 2004-819602 | 20041118 <-- |
| R: AT, BE, CH,
IE, SI, LT,
HR, IS, YU | DE, DK, ES,
LV, FI, RO,
CY, AL, TR,
BG, CZ, EE, | FR, GB, GR, IT,
LU, NL, SE, MC, PT,
HU, PL, SK, | | |
| CN 1890224 | A | 20070103 | CN 2004-80035857 | 20041118 <-- |
| BR 2004016532 | A | 20070109 | BR 2004-16532 | 20041118 <-- |
| JP 2007513101 | T | 20070524 | JP 2006-541830 | 20041118 <-- |
| SG 151249 | A1 | 20090430 | SG 2009-1531 | 20041118 <-- |
| IN 2006DN03071 | A | 20070810 | IN 2006-DN3071 | 20060529 <-- |
| US 20070129375 | A1 | 20070607 | US 2006-596086 | 20060530 <-- |
| MX 2006006255 | A | 20060809 | MX 2006-6255 | 20060602 <-- |
| KR 2006118534 | A | 20061123 | KR 2006-711234 | 20060608 <-- |
| NO 2006003028 | A | 20060628 | NO 2006-3028 | 20060628 <-- |
| PRIORITY APPLN. INFO.: | | | EP 2003-78859 | A 20031205 <-- |
| | | | WO 2004-EP13164 | W 20041118 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:60003; MARPAT 143:60003

GI



AB The title compds. I [n = 0-2; X = N, CR5; R5 = H or taken together with R1 may form CH:CHCH:CH; R1 = alkyl, thiienyl; R2 = H, OH, or taken together with R3 or R4 may form O; R3 = OH, OR8, SR9, etc.; R8 = alkyl, alkylcarbonyl, dialkylaminoalkyl; R9 = dialkylaminoalkyl; R4 = H, alkyl, furanyl, etc.; with the provision], useful for the treatment of a PARP mediated disorder, were prepared E.g., a multi-step synthesis of II, starting from 1-(4-amino-3-nitrophenyl)-2-methyl-1-propanone, was given. The exemplified compds. I were tested in an *in vitro* assay based on SPA technol. and in an *in vitro* filtration assay assessing PARP-1 activity (data given). The pharmaceutical composition comprising the compound I is disclosed.


IT 854523-82-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 6-substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)

RN 854523-82-3 CAPLUS

CN Formamide, N-[1-(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)-3-phenylpropyl]-
(CA INDEX NAME)



IT 854524-08-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 6-substituted 2-quinolinones and 2-quinoxalinones as
 poly(ADP-ribose) polymerase inhibitors)
 RN 854524-08-6 CAPLUS
 CN 2(1H)-Quinolinone, 3-methyl-6-(1-oxo-3-phenylpropyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:523424 CAPLUS
 DOCUMENT NUMBER: 143:60001
 TITLE: Preparation of 6-alkenyl and 6-phenylalkyl substituted
 2-quinolinones and 2-quinoxalinones as
 poly(ADP-ribose) polymerase inhibitors
 INVENTOR(S): Mabire, Dominique Jean-pierre; Guillemont, Jerome
 Emile Georges; Van Dun, Jacobus Alphonsus Josephus;
 Somers, Maria Victorina Francisca; Wouters, Walter
 Boudewijn Leopold
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:



| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|------------------|--------------|
| WO 2005054201 | A1 | 20050616 | WO 2004-EP13163 | 20041118 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, T2, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG | | | | |
| AU 2004295058 | A1 | 20050616 | AU 2004-295058 | 20041118 <-- |
| CA 2546300 | A1 | 20050616 | CA 2004-2546300 | 20041118 <-- |
| EP 1687277 | A1 | 20060809 | EP 2004-819601 | 20041118 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| CN 1882547 | A | 20061220 | CN 2004-80034176 | 20041118 <-- |

| | | | | |
|------------------------|----|----------|-----------------|----------------|
| BR 2004016206 | A | 20061226 | BR 2004-16206 | 20041118 <-- |
| JP 2007511574 | T | 20070510 | JP 2006-540338 | 20041118 <-- |
| SG 150533 | A1 | 20090330 | SG 2009-1197 | 20041118 <-- |
| NZ 546991 | A | 20100129 | NZ 2004-546991 | 20041118 <-- |
| US 20070072842 | A1 | 20070329 | US 2006-595891 | 20060518 <-- |
| IN 2006DN02813 | A | 20070803 | IN 2006-DN2813 | 20060518 <-- |
| MX 2006005687 | A | 20060817 | MX 2006-5687 | 20060519 <-- |
| ZA 2006004075 | A | 20070926 | ZA 2006-4075 | 20060519 <-- |
| KR 2006115393 | A | 20061108 | KR 2006-710201 | 20060525 <-- |
| NO 2006002894 | A | 20060809 | NO 2006-2894 | 20060620 <-- |
| PRIORITY APPLN. INFO.: | | | WO 2003-EP13028 | A 20031120 <-- |
| | | | EP 2003-78860 | A 20031205 <-- |
| | | | WO 2003-EP130 | A 20031120 <-- |
| | | | WO 2004-EP13163 | W 20041118 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:60001; MARPAT 143:60001

GI



AB The title compds. I [n = 0-2; X = N, CR7; R7 = H or taken together with R1 may form CH:CHCH:CH; R1 = alkyl, thiophenyl; R2 = H, OH, alkyl, alkynyl or taken together with R3 may form O; R3 = OH, OR10, SR11, etc.; R10, R11 = CHO, alkyl, (alkyl)amino, etc.; R4-R6 = H, halo, trihalomethyl, etc.; with the provision], useful for the treatment of a PARP mediated disorder, were prepared. E.g., a multi-step synthesis of II, starting from bromobenzene and 3-methyl-6-quinolinecarboxaldehyde, was given. The exemplified compds. I were tested in an *in vitro* assay based on SPA technol. and in an *in vitro* filtration assay assessing PARP-1 activity (data given). The pharmaceutical composition comprising the compound I is disclosed.


IT 854532-59-5P 854532-61-9P 854533-52-1P
854533-95-2P 854534-00-2P 854534-03-5P

854534-17-1P 854534-18-2P 854534-19-3P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)


RN 854532-59-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)carbonyl]-3-ethyl-
(CA INDEX NAME)




RN 854532-61-9 CAPLUS
CN 6-Quinolineacetonitrile, 1,2-dihydro-3-methyl-2-oxo- α -phenyl- (CA
INDEX NAME)




RN 854533-52-1 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-oxo-1-piperidinyl)phenylmethyl]- (CA
INDEX NAME)




RN 854533-95-2 CAPLUS
CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)phenylmethyl]- (CA
INDEX NAME)



RN 854534-00-2 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-(hydroxyphenylmethyl)- (CA INDEX NAME)




RN 854534-03-5 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-oxoethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-17-1 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(1Z)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 854534-18-2 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(1E)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 854534-19-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[{(2,3-dihydro-1,4-benzodioxin-6-yl)-4-piperidinylidenemethyl]-3-ethyl- (CA INDEX NAME)




| | | | |
|----|--------------|--------------|--------------|
| IT | 130346-68-8P | 130346-69-9P | 854532-58-4P |
| | 854532-60-8P | 854532-62-0P | 854532-63-1P |
| | 854532-64-2P | 854532-65-3P | 854532-66-4P |
| | 854532-67-5P | 854532-69-7P | 854532-70-0P |
| | 854532-71-1P | 854532-72-2P | 854532-73-3P |
| | 854532-74-4P | 854532-75-5P | 854532-76-6P |
| | 854532-77-7P | 854532-78-8P | 854532-79-9P |
| | 854532-80-2P | 854532-81-3P | 854532-82-4P |
| | 854532-83-5P | 854532-84-6P | 854532-85-7P |
| | 854532-86-8P | 854532-87-9P | 854532-89-1P |
| | 854532-92-6P | 854532-93-7P | 854532-94-8P |
| | 854532-95-9P | 854532-96-0P | 854532-97-1P |
| | 854532-98-2P | 854533-00-9P | 854533-02-1P |
| | 854533-04-3P | 854533-06-5P | 854533-07-6P |
| | 854533-09-8P | 854533-14-5P | 854533-16-7P |
| | 854533-18-9P | 854533-20-3P | 854533-21-4P |
| | 854533-23-6P | 854533-25-8P | 854533-27-0P |
| | 854533-29-2P | 854533-30-5P | 854533-31-6P |
| | 854533-32-7P | 854533-33-8P | 854533-34-9P |
| | 854533-35-0P | 854533-36-1P | 854533-37-2P |
| | 854533-38-3P | 854533-39-4P | 854533-40-7P |
| | 854533-41-8P | 854533-42-9P | 854533-43-0P |
| | 854533-44-1P | 854533-45-2P | 854533-46-3P |
| | 854533-47-4P | 854533-48-5P | 854533-49-6P |
| | 854533-51-0P | 854533-53-2P | 854533-54-3P |
| | 854533-55-4P | 854533-56-5P | 854533-57-6P |
| | 854533-58-7P | 854533-59-8P | 854533-60-1P |
| | 854533-62-3P | 854533-65-6P | 854533-67-8P |
| | 854533-69-0P | 854533-71-4P | 854533-73-6P |
| | 854533-75-8P | 854533-79-2P | 854533-81-6P |
| | 854533-83-8P | 854533-85-0P | 854533-87-2P |
| | 854533-89-4P | 854533-91-8P | 854533-93-0P |
| | 854533-97-4P | 854533-98-5P | 854533-99-6P |
| | 854534-01-3P | 854534-02-4P | 854534-04-6P |
| | 854534-05-7P | 854534-06-8P | 854534-07-9P |
| | 854534-08-0P | 854534-09-1P | 854534-10-4P |
| | 854534-11-5P | 854534-12-6P | 854534-13-7P |
| | 854534-14-8P | 854534-15-9P | 854534-16-0P |
| | 854534-20-6P | 854534-21-7P | 854534-22-8P |
| | 854534-23-9P | 854534-24-0P | 854534-25-1P |
| | 854534-26-2P | 854534-27-3P | 854534-28-4P |
| | 854534-29-5P | 854534-30-8P | 854534-31-9P |
| | 854534-32-0P | 854534-33-1P | 854535-35-6P |


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 6-alkenyl and 6-phenylalkyl substituted 2-quinalinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)


RN 130346-68-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[1H-imidazol-1-yl(4-methoxyphenyl)methyl]-3-methyl-
(CA INDEX NAME)




RN 130346-69-9 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)




RN 854532-58-4 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[(methylamino)phenylmethyl]- (CA INDEX NAME)




RN 854532-60-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(acetyloxy)phenylmethyl]-3-ethyl- (CA INDEX NAME)




RN 854532-62-0 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-(phenyl-1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 854532-63-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[(dimethylamino)phenylmethyl]-3-methyl- (CA INDEX NAME)




RN 854532-64-2 CAPLUS
CN Urea, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)phenylmethyl]-N'-(3-(1-piperidinyl)propyl)- (CA INDEX NAME)




RN 854532-65-3 CAPLUS
CN Acetamide, N-[2-(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)-2-phenylethyl]- (CA INDEX NAME)




RN 854532-66-4 CAPLUS
CN 2(1H)-Quinolinone, 6-(methoxyphenylmethyl)-3-methyl- (CA INDEX NAME)




RN 854532-67-5 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[(1-methyl-1H-imidazol-5-yl)phenylmethyl]-
(CA INDEX NAME)



RN 854532-69-7 CAPLUS
CN 2(1H)-Quinolinone, 6-(1,3-benzodioxol-5-ylhydroxymethyl)-3-ethyl- (CA
INDEX NAME)




RN 854532-70-0 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl]phenylmethyl]- (CA INDEX NAME)




RN 854532-71-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[(2E)-3-phenyl-2-propen-1-yl]-4-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 854532-72-2 CAPLUS
 CN Piperidinium, 4-[(2,3-dihydro-1,4-benzodioxin-6-yl)(3-ethyl-1,2-dihydro-2-oxo-6-quinolinyl)methyl]-1,1-bis[(2E)-3-phenyl-2-propen-1-yl]-, chloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.




● Cl⁻


RN 854532-73-3 CAPLUS
 CN 2(1H)-Quinolinone, 6-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)propyl]-3-ethyl- (CA INDEX NAME)




RN 854532-74-4 CAPLUS
 CN 2(1H)-Quinolinone, 3-ethyl-6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)




RN 854532-75-5 CAPLUS
 CN Formamide, N-[(2,3-dihydro-1,4-benzodioxin-6-yl)(3-ethyl-1,2-dihydro-2-oxo-6-quinolinyl)methyl]- (CA INDEX NAME)




RN 854532-76-6 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-hydroxyethyl]-3-ethyl- (CA INDEX NAME)




RN 854532-77-7 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(1H-imidazol-1-yl)ethyl]-3-ethyl- (CA INDEX NAME)




RN 854532-78-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(1-pyrrolidinyl)ethyl]-3-ethyl- (CA INDEX NAME)




RN 854532-79-9 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[{(4-chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl}-3-ethyl- (CA INDEX NAME)




RN 854532-80-2 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[phenyl[[3-(2-thienyl)propyl]amino]methyl]- (CA INDEX NAME)




RN 854532-81-3 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[phenyl[(3-(1H-pyrrol-1-yl)propyl)amino]methyl]- (CA INDEX NAME)




RN 854532-82-4 CAPLUS
CN Acetamide, N-[2-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)phenylmethyl]amino]ethyl- (CA INDEX NAME)




RN 854532-83-5 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[phenyl[(3-(1-piperidinyl)propyl)amino]methyl]- (CA INDEX NAME)




RN 854532-84-6 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[(3-oxo-3-phenylpropyl)amino]phenylmethyl- (CA INDEX NAME)




RN 854532-85-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2-(dimethylamino)ethoxy]phenylmethyl]-3-ethyl- (CA INDEX NAME)



RN 854532-86-8 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(2-hydroxyethyl)amino]phenylmethyl]-3-methyl- (CA INDEX NAME)




RN 854532-87-9 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-6-(phenyl-1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)



RN 854532-89-1 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[2-(1-piperidinyl)ethyl]-1-piperidinyl]methyl]-3-ethyl-, ethanedioate (2:5) (CA INDEX NAME)

CM 1

CRN 854532-88-0
 CMF C32 H41 N3 O3




CM 2


CRN 144-62-7
CMF C2 H2 O4




RN 854532-92-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854532-93-7 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl][3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 854532-94-8 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(2-fluoro-4-(trifluoromethyl)phenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]- (CA INDEX NAME)




RN 854532-95-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[[4-[3-(dimethylamino)propoxy]phenyl][4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854532-96-0 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-oxo-1-piperidinyl)[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 854532-97-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)(4-oxo-1-piperidinyl)methyl]-3-ethyl-
(CA INDEX NAME)




RN 854532-98-2 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-methyl-1-piperazinyl)phenylmethyl]- (CA
INDEX NAME)



RN 854533-00-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[(2-(1-piperidinyl)ethyl]1-piperazinyl]methyl]-3-ethyl-, ethanedioate (1:3) (CA
INDEX NAME)

CM 1

CRN 854532-99-3
CMF C31 H40 N4 O3



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 854533-02-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-(cyclohexylmethyl)-1-piperazinyl)(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-3-ethyl-, ethanedioate (2:3) (CA INDEX NAME)

CM 1

CRN 854533-01-0
CMF C31 H39 N3 O3




CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 854533-04-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[1,3-benzodioxol-5-yl[6-fluoro-3-(4-piperidinyl)-1H-indazol-1-yl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-06-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[1,(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1-piperazinyl]methyl]-3-ethyl-, ethanedioate (2:5) (CA INDEX NAME)

CM 1

CRN 854533-05-4
CMF C32 H42 N4 O3




CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 854533-07-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl){[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]amino}methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-09-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl){4-(6-fluoro-1H-indazol-3-yl)-1-piperidinyl}methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-14-5 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-[[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]amino]phenylmethyl-, ethanedioate (2:5) (CA INDEX NAME)

CM 1

CRN 854533-13-4

CMF C31 H33 F N4 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 854533-16-7 CAPLUS

CN 2(1H)-Quinoxalinone, 3-ethyl-6-[phenyl[[(3-(1-piperidinyl)propyl)amino]methyl]-, ethanedioate (2:5) (CA INDEX NAME)

CM 1

CRN 854533-15-6

CMF C25 H32 N4 O



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 854533-18-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[[(3-(1-piperidinyl)propyl)amino]methyl]-3-ethyl-, ethanedioate (1:2) (CA INDEX NAME)

CM 1

CRN 854533-17-8

CMF C28 H35 N3 O3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 854533-20-3 CAPLUS

CN 6-(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl){[1-(phenylmethyl)-3-piperidinyl]amino}methyl]-3-ethyl-, ethanedioate (2:5) (CA INDEX NAME)

CM 1

CRN 854533-19-0

CMF C32 H35 N3 O3




CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 854533-21-4 CAPLUS
 CN 2(1H)-Quinolinone, 6-[1,3-benzodioxol-5-yl[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-23-6 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[2-(dimethylamino)ethoxy]methyl]-3-ethyl-, ethanedioate (2:3) (CA INDEX NAME)

CM 1

CRN 854533-22-5
 CMF C24 H28 N2 O4



CM 2


CRN 144-62-7
 CMF C2 H2 O4



RN 854533-25-8 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-6-[[3-[methyl(phenylmethyl)amino]propyl]amino]phenylmethyl]-, ethanedioate (1:2) (CA INDEX NAME)

CM 1

CRN 854533-24-7
CMF C28 H32 N4 O



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 854533-27-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[[3-[methyl(phenylmethyl)aminolpropyl]amino]methyl]-3-ethyl-, ethanedioate (1:2) (CA INDEX NAME)

CM 1

CRN 854533-26-9
CMF C31 H35 N3 O3



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 854533-29-2 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(2-methoxyethyl)aminolphenylmethyl]-, ethanedioate (1:2) (CA INDEX NAME)

CM 1

CRN 854533-28-1
CMF C21 H24 N2 O2




CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 854533-30-5 CAPLUS


CN 2(1H)-Quinolinone, 3-ethyl-6-[(3-fluorophenyl)(4-[(2-methoxyethyl)amino]-1-piperidinyl)methyl]- (CA INDEX NAME)



MeO-CH₂-CH₂-NH


RN 854533-31-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)(4-methyl-1-piperazinyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-32-7 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-[(2-methoxyethyl)amino]-1-piperidinyl)-2-naphthalenylmethyl]- (CA INDEX NAME)




RN 854533-33-8 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[(2-fluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]- (CA INDEX NAME)




RN 854533-34-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[(4-chloro-3-fluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-35-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,4-dimethylphenyl)(4-[(2-methoxyethyl)amino]-1-piperidinyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-36-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[(4-(dimethylamino)phenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-37-2 CAPLUS


CN 2(1H)-Quinolinone, 6-[(2,4-dichlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-38-3 CAPLUS
 CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-fluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]- (CA INDEX NAME)




RN 854533-39-4 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(2,4-difluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-40-7 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(2-chloro-5-(trifluoromethyl)phenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-41-8 CAPLUS
 CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-[(2-methoxyethyl)amino]-1-piperidinyl)methyl]-[4-(trifluoromethyl)phenyl]methyl- (CA INDEX NAME)



RN 854533-42-9 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)[2-(dimethylamino)ethoxy]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-43-0 CAPLUS
 CN 2(1H)-Quinolinone, 3-ethyl-6-[4H-1,2,4-triazol-4-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 854533-44-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,6-dichlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-45-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2-chlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-46-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)(4-methyl-1-piperazinyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-47-4 CAPLUS


CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl]-1-naphthalenylmethyl]- (CA INDEX NAME)



RN 854533-48-5 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)(4-oxo-1-piperidinyl)methyl]-3-ethyl-
 (CA INDEX NAME)




RN 854533-49-6 CAPLUS
 CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-methyl-1-piperazinyl)(3-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)



RN 854533-51-0 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(2-(dimethylamino)ethoxy)(3-(trifluoromethyl)phenyl)methyl]-3-ethyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 854533-50-9
 CMF C23 H25 F3 N2 O2




CM 2


CRN 144-62-7
CMF C2 H2 O4




RN 854533-53-2 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-[(2-methoxyethyl)amino]-1-piperidinyl)(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 854533-54-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[(3,4-dichlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-55-4 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-[(4-oxo-1-piperidinyl)phenylmethyl]- (CA INDEX NAME)




RN 854533-56-5 CAPLUS
CN 6-Quinolineacetonitrile, 1,2-dihydro- α ,3-dimethyl-2-oxo- α -phenyl- (CA INDEX NAME)




RN 854533-57-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-58-7 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl][3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 854533-59-8 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[(1-methyl-3-piperidinyl)phenylmethyl]- (CA INDEX NAME)



RN 854533-60-1 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[1-phenyl-3-(1-piperidinyl)propyl]- (CA INDEX NAME)




RN 854533-62-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(dimethylamino)propyl]-3-ethyl- (CA INDEX NAME)



RN 854533-65-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-(dimethylamino)-1-[3-(trifluoromethyl)phenyl]propyl]-3-ethyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 854533-64-5
CMF C23 H25 F3 N2 O




CM 2


CRN 144-62-7
CMF C2 H2 O4




RN 854533-67-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-(dimethylamino)-1-phenylpropyl]-3-ethyl- (CA INDEX NAME)




RN 854533-69-0 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-(phenyl-1-piperidinylmethyl)- (CA INDEX NAME)




RN 854533-71-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)




RN 854533-73-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)




RN 854533-75-8 CAPLUS
 CN Formamide, N-[(3-ethyl-1,2-dihydro-2-oxo-6-quinolinyl)phenylmethyl]- (CA INDEX NAME)




RN 854533-79-2 CAPLUS
 CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)(3-methylphenyl)methyl]- (CA INDEX NAME)




RN 854533-81-6 CAPLUS
 CN Formamide, N-[1,3-benzodioxol-5-yl(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)methyl]- (CA INDEX NAME)




RN 854533-83-8 CAPLUS
 CN Benzoic acid, 4-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)(formylamino)methyl]-, ethyl ester (CA INDEX NAME)




RN 854533-85-0 CAPLUS
CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)(3-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 854533-87-2 CAPLUS
CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)(4-fluorophenyl)methyl]- (CA INDEX NAME)




RN 854533-89-4 CAPLUS
CN Formamide, N-[3-(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)-1-phenylpropyl]- (CA INDEX NAME)




RN 854533-91-8 CAPLUS
CN Formamide, N-[(3-chlorophenyl)(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)methyl]- (CA INDEX NAME)




RN 854533-93-0 CAPLUS
CN Formamide, N-[(4-chlorophenyl)(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)methyl]- (CA INDEX NAME)




RN 854533-97-4 CAPLUS
 CN 2(1H)-Quinolinone, 6-[hydroxy(3-methoxyphenyl)methyl]-3-methyl- (CA INDEX NAME)




RN 854533-98-5 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-6-(2-hydroxy-2-phenylethyl)- (CA INDEX NAME)



RN 854533-99-6 CAPLUS
 CN Benzoic acid, 4-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)hydroxymethyl]-, ethyl ester (CA INDEX NAME)




RN 854534-01-3 CAPLUS
 CN 2(1H)-Quinolinone, 6-(1,3-benzodioxol-5-ylhydroxymethyl)-3-methyl- (CA INDEX NAME)




RN 854534-02-4 CAPLUS

CN 2(1H)-Quinolinone, 6-(1-hydroxy-1-phenyl-2-propyn-1-yl)-3-methyl- (CA INDEX NAME)




RN 854534-04-6 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(1-piperidinyl)ethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-05-7 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 854534-06-8 CAPLUS

CN 2(1H)-Quinoxalinone, 3-ethyl-6-(2-oxo-2-phenylethyl)- (CA INDEX NAME)




RN 854534-07-9 CAPLUS


CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(4-cyclohexyl-1-piperazinyl)ethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-08-0 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[3-(4-chlorophenyl)-3-(1H-imidazol-1-yl)propyl]-3-ethyl- (CA INDEX NAME)




RN 854534-09-1 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-6-[2-(1H-imidazol-1-yl)-2-phenylethyl]- (CA INDEX NAME)



RN 854534-10-4 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[1-(4-chlorophenyl)-2-(3-ethyl-1,2-dihydro-2-oxo-6-quinoxalinyl)ethyl]- (CA INDEX NAME)




RN 854534-11-5 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(4-hydroxy-4-phenyl-1-piperidinyl)ethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-12-6 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)(4-methyl-1H-imidazol-1-yl)methyl]-3-ethyl- (CA INDEX NAME)




RN 854534-13-7 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-14-8 CAPLUS


CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1-piperidinylmethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-15-9 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]-
(CA INDEX NAME)




RN 854534-16-0 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-ethyl-
(CA INDEX NAME)




RN 854534-20-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)




RN 854534-21-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[{(2,3-dihydro-1,4-benzodioxin-6-yl)[1-{[2-hydroxy-3-(4-methoxyphenoxy)propyl]-4-piperidinylidene]methyl}-3-ethyl- (CA INDEX NAME)



RN 854534-22-8 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[(1-methyl-3-piperidinylidene)phenylmethyl]- (CA INDEX NAME)




RN 854534-23-9 CAPLUS
CN 2(1H)-Quinolinone, 5-[1-(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)-3-(dimethylamino)-1-propen-1-yl]-3-methyl- (CA INDEX NAME)




RN 854534-24-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[(1E)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(dimethylamino)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 854534-25-1 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(1Z)-1-(4-chlorophenyl)-3-(dimethylamino)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 854534-26-2 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(1Z)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(dimethylamino)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 854534-27-3 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(1E)-3-(dimethylamino)-1-phenyl-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 854534-28-4 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(1Z)-3-(dimethylamino)-1-phenyl-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 854534-29-5 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)




RN 854534-30-8 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[(2E)-3-phenyl-2-propen-1-yl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 854534-31-9 CAPLUS


CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[3-(4-fluorophenoxy)-2-hydroxypropyl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)



RN 854534-32-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[(1R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)propyl]-3-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 854534-33-1 CAPLUS


CN 2(1H)-Quinolinone, 6-[(1S)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)propyl]-3-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 854535-35-6 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



IT 854534-37-5P 854534-38-6P 854534-40-0P

854534-42-2P 854534-48-8P 854534-49-9P


854534-50-2P 854534-51-3P 854534-52-4P

854534-53-5P 854534-62-6P 854534-64-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)


RN 854534-37-5 CAPLUS
CN 2(1H)-Quinolinone, 6-benzoyl-3-methyl- (CA INDEX NAME)




RN 854534-38-6 CAPLUS
CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)phenylmethyl]-N-methyl- (CA INDEX NAME)




RN 854534-40-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)hydroxymethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-42-2 CAPLUS
CN 2(1H)-Quinolinone, 6-benzoyl-3-ethyl- (CA INDEX NAME)



RN 854534-48-8 CAPLUS
CN 2(1H)-Quinolinone, 6-(aminophenylmethyl)-3-methyl- (CA INDEX NAME)




RN 854534-49-9 CAPLUS
CN 2(1H)-Quinolinone, 6-(aminophenylmethyl)-3-methyl-, hydrochloride (1:1)
(CA INDEX NAME)




● HCl


RN 854534-50-2 CAPLUS
CN 2(1H)-Quinolinone, 6-(isocyanatophenylmethyl)-3-methyl- (CA INDEX NAME)




RN 854534-51-3 CAPLUS
CN 2(1H)-Quinolinone, 6-(2-amino-1-phenylethyl)-3-methyl- (CA INDEX NAME)




RN 854534-52-4 CAPLUS
CN 2(1H)-Quinolinone, 6-(hydroxyphenylmethyl)-3-methyl- (CA INDEX NAME)




RN 854534-53-5 CAPLUS
CN 2(1H)-Quinolinone, 6-(chlorophenylmethyl)-3-methyl- (CA INDEX NAME)



RN 854534-62-6 CAPLUS
CN 2(1H)-Quinolinone, 6-(chlorophenylmethyl)-3-ethyl- (CA INDEX NAME)



RN 854534-64-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)-4-piperidinylmethyl]-3-ethyl- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:430796 CAPLUS
DOCUMENT NUMBER: 141:7139
TITLE: Preparation of indolylquinoxalinones for treating hyperproliferative disorders and diseases associated with angiogenesis

INVENTOR(S):

Ladouceur, Gaetan H.; Bear, Brian; Bi, Cheng;
 Brittelli, David R.; Burke, Michael J.; Chen, Gang;
 Cook, James; Dumas, Jacques; Sibley, Robert; Turner,
 Michael R.

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 217 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|----------------|
| WO 2004043950 | A1 | 20040527 | WO 2003-US36003 | 20031110 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2505819 | A1 | 20040527 | CA 2003-2505819 | 20031110 <-- |
| AU 2003290744 | A1 | 20040603 | AU 2003-290744 | 20031110 <-- |
| EP 1565455 | A1 | 20050824 | EP 2003-783328 | 20031110 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003016169 | A | 20050927 | BR 2003-16169 | 20031110 <-- |
| CN 1738814 | A | 20060222 | CN 2003-80108639 | 20031110 <-- |
| JP 2006509840 | T | 20060323 | JP 2005-507146 | 20031110 <-- |
| MX 2005004779 | A | 20050722 | MX 2005-4779 | 20050504 <-- |
| US 20060004011 | A1 | 20060105 | US 2005-534215 | 20050506 <-- |
| NO 2005002796 | A | 20050609 | NO 2005-2796 | 20050609 <-- |
| PRIORITY APPLN. INFO.: | | | US 2002-425490P | P 20021112 <-- |
| | | | US 2003-460915P | P 20030407 <-- |
| | | | US 2003-484202P | P 20030630 <-- |
| | | | WO 2003-US36003 | W 20031110 <-- |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 141:7139

GI



AB The invention relates to title compds. I [wherein Ar = 6-membered aromatic ring containing 0-2 N atoms; R1 and R2 = independently H, halo, CF₃, acyl, piperidinyl, piperazinyl, morpholinyl, or (un)substituted alkyl, alkoxy,

amino, pyrrolidinyl, Ph, etc.; R3 = H, alkyl, OH, NO₂, NH₂, alkylamino, alkoxyamino, or (un)substituted benzoylamino; R4 = H, OH, halo, CN, acyl, sulfamoyl, trialkylsiloxy, tetrazolyl, thiienyl, pyrrolyl, pyrimidinyl, oxazolyl, furanyl, or (un)substituted alkyl, alkenyl, alkynyl, alkoxy, amino, oxadiazolyl, Ph, pyridyl(oxy), carbamoyl; R11 and R12 = independently H, F, or Cl with the proviso that when one of R11 and R12 = F or Cl, the other must be H; and pharmaceutically acceptable salts and esters thereof]. The invention also relates to the use of I and their pharmaceutical compns. for treating hyperproliferative disorders and diseases associated with angiogenesis (no data). Examples include representative syntheses for compds. of the invention, pharmaceutical compns. comprising them, and tumor model assays (no specific data given). For instance, N-Boc-indole was coupled with di-Me oxalate using t-BuLi to give tert-Bu 2-[methoxy(oxo)acetyl]-1H-indole-1-carboxylate (72%). Cyclization of the dione with 1,2-phenylenediamine in AcOH afforded the quinoxalinone II (77%).

IT 694531-84-5P 694531-85-6P 694531-86-7P

694531-93-6P 694532-04-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antiproliferative and angiogenesis inhibitor; preparation of indolylquinoxalinones for treating hyperproliferative disorders and diseases associated with angiogenesis)

RN 694531-84-5 CAPLUS


CN 2(1H)-Quinoxalinone, 3-[3-amino-5-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl]-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 694531-85-6 CAPLUS

CN 2(1H)-Quinoxalinone, 3-[3-amino-5-[[4-(2-methoxyethyl)-1-piperazinyl]carbonyl]-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)




RN 694531-86-7 CAPLUS


CN 2(1H)-Quinoxalinone, 3-[3-amino-5-(1-piperidinylcarbonyl)-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)



RN 694531-93-6 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-[3-amino-5-(1-pyrrolidinylcarbonyl)-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)



RN 694532-04-2 CAPLUS
 CN 1H-Indole-5-carboxylic acid, 3-amino-2-(7-benzoyl-3,4-dihydro-3-oxo-2-quinoxalinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
 (9 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT




L7 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2003:796538 CAPLUS
 DOCUMENT NUMBER: 139:323440
 TITLE: Preparation of radiolabeled quinolines and
 quinolinones as metabotropic glutamate receptor mGluR1
 antagonists for use in positron emission tomography.
 Lesage, Anne Simone Josephine; Bischoff, Francois
 Paul; Janssen, Cornelius Gerardus Maria; Lavreyse, Hilde
 INVENTOR(S):
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 148 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------------|
| WO 2003082350 | A2 | 20031009 | WO 2003-EP3240 | 20030326 <-- |
| WO 2003082350 | A3 | 20040304 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2479109 | A1 | 20031009 | CA 2003-2479109 | 20030326 <-- |
| AU 2003226737 | A1 | 20031013 | AU 2003-226737 | 20030326 <-- |
| AU 2003226737 | B2 | 20080904 | | |
| BR 200308945 | A | 20050104 | BR 2003-8945 | 20030326 <-- |
| EP 1492571 | A2 | 20050105 | EP 2003-745282 | 20030326 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| CN 1642580 | A | 20050720 | CN 2003-807387 | 20030326 <-- |
| JP 2005524679 | T | 20050818 | JP 2003-579882 | 20030326 <-- |
| NZ 535438 | A | 20060831 | NZ 2003-535438 | 20030326 <-- |
| IN 2004DN02631 | A | 20050401 | IN 2004-DN2631 | 20040908 <-- |
| US 20060083676 | A1 | 20060420 | US 2004-509069 | 20040924 <-- |
| US 7517517 | B2 | 20090414 | | |
| MX 2004009435 | A | 20050125 | MX 2004-9435 | 20040928 <-- |
| ZA 2004007820 | A | 20051011 | ZA 2004-7820 | 20040928 <-- |
| NO 2004004635 | A | 20041027 | NO 2004-4635 | 20041027 <-- |
| PRIORITY APPLN. INFO.: | | | EP 2002-76254 | A 20020329 <-- |
| | | | WO 2003-EP3240 | W 20030326 <-- |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:323440

GT



AB Radiolabeled title compds. [I, II; X = O, S, C(R6)2, NR7; Y = O, S; R1 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, thiienyl, quinolinyl, etc.; R2 = H, halo, cyano, alkyl, amino, heterocyclyl, etc.; R3, R4 = H, halo, OH, cyano, alkyl, alkoxy, etc.; R2R3 = (CH2)3-6, Z4CH2CH2CH2, Z4CH2CH2, etc.; Z4 = O, S, SO2, NR11; R11 = H, alkyl, PhCH2, alkoxy carbonyl; R3R4 = (CH2)4, CH:CHCH2:CH; R5 = H, cycloalkyl, piperidinyl, oxothienyl, tetrahydrothienyl, aralkyl, alkoxyalkyl, etc.; R6 =

= H, aryl, alkyl, aminoalkyl; R7 = amino, OH], were prepared. Most preferred are radiolabeled compds. in which the radioactive isotope is selected from 3H, 11C and 18F. The invention also relates to their use in a diagnostic method, in particular for marking and identifying a mGluR1 receptor in biol. material, as well as to their use for imaging an organ, in particular using positron emission tomog. (PET). Thus, title compound (III) was prepared by tritiation of the corresponding bromide in THF using tritium gas and Pd/C catalyst. The purified product showed specific activity of 25 Ci/mmol.


IT 409344-47-4P 409344-48-5P 409344-56-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of radiolabeled quinolines and quinolinones as metabotropic glutamate receptor mGluR1 antagonists for use in positron emission tomog.)


RN 409344-47-4 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-(2-phenylacetyl)- (CA INDEX NAME)




RN 409344-48-5 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[2-(2-methoxyphenyl)acetyl]- (CA INDEX NAME)



RN 409344-56-5 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-(1-oxo-3-phenylpropyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:275968 CAPLUS




DOCUMENT NUMBER: 136:309857

TITLE: Preparation of quinolines and quinolinones as

INVENTOR(S): metabotropic glutamate receptor antagonists
 Mabire, Dominique Jean-Pierre; Venet, Marc Gaston;
 Coupa, Sophie; Poncelet, Alain Philippe; Lesage, Anne
 Simone Josephine
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 114 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|-----------------|
| WO 2002028837 | A1 | 20020411 | WO 2001-EP11135 | 20010925 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2421782 | A1 | 20020411 | CA 2001-2421782 | 20010925 <-- |
| AU 2001093847 | A | 20020415 | AU 2001-93847 | 20010925 <-- |
| BR 2001014253 | A | 20030701 | BR 2001-14253 | 20010925 <-- |
| EP 1332133 | A1 | 20030806 | EP 2001-974298 | 20010925 <-- |
| EP 1332133 | B1 | 20080709 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| HU 2003002167 | A2 | 20031028 | HU 2003-2167 | 20010925 <-- |
| JP 2004510764 | T | 20040408 | JP 2002-532423 | 20010925 <-- |
| NZ 524945 | A | 20050128 | NZ 2001-524945 | 20010925 <-- |
| EE 200300126 | A | 20050415 | EE 2003-126 | 20010925 <-- |
| EE 5195 | B1 | 20090817 | | |
| CN 1703403 | A | 20051130 | CN 2001-816717 | 20010925 <-- |
| AU 2001293847 | B2 | 20070524 | AU 2001-293847 | 20010925 <-- |
| AT 400558 | T | 20080715 | AT 2001-974298 | 20010925 <-- |
| ES 2309095 | T3 | 20081216 | ES 2001-974298 | 20010925 <-- |
| IL 155163 | A | 20090803 | IL 2001-155163 | 20010925 <-- |
| TW 306854 | B | 20090301 | TW 2001-90124220 | 20011002 <-- |
| KR 818965 | B1 | 20080404 | KR 2003-702014 | 20030211 <-- |
| HR 2003000229 | A2 | 20030630 | HR 2003-229 | 20030324 <-- |
| IN 2003MN00328 | A | 20050211 | IN 2003-MN328 | 20030324 <-- |
| BG 107672 | A | 20040130 | BG 2003-107672 | 20030326 <-- |
| ZA 2003002515 | A | 20040630 | ZA 2003-2515 | 20030331 <-- |
| NO 2003001474 | A | 20030505 | NO 2003-1474 | 20030401 <-- |
| NO 325079 | B1 | 20080128 | | |
| MX 2003002907 | A | 20030624 | MX 2003-2907 | 20030401 <-- |
| US 20040082592 | A1 | 20040429 | US 2003-381987 | 20030814 <-- |
| US 7115630 | B2 | 20061003 | | |
| US 20050209273 | A1 | 20050922 | US 2005-133678 | 20050520 <-- |
| US 7629468 | B2 | 20091208 | | |
| PRIORITY APPLN. INFO.: | | | EP 2000-203419 | A 20010102 <-- |
| | | | WO 2001-EP11135 | W 20010925 <-- |
| | | | US 2003-381987 | A3 20030814 <-- |

OTHER SOURCE(S): MARPAT 136:309857
 GI



AB The title compds. [I or II; X = O, C(R₆)₂; (wherein R₆ = H, aryl, alkyl, etc.); R₁ = alkyl, aryl, thienyl, etc.; R₂ = H, halo, CN, etc.; R₃, R₄ = H, alkyl; or R₂ and R₃ may be taken together to form (CH₂)₃, (CH₂)₄, CH:CHCH:CH, etc.; or R₃ and R₄ may be taken together to form CH:CHCH:CH, (CH₂)₄; R₅ = H, cycloalkyl, piperidinyl, etc.; Y = O, S; or Y and R₅ may be taken together to form CH:NN, N:NN, NCH:CH], useful for treating or preventing glutamate-induced diseases of the central nervous system, were prepared. Thus, reacting cis-III [R = Cl] with SnMe₄ in the presence of Pg(PPh₃)₄ in PhMe afforded 17% cis-III [R = Me] which showed antagonism at a dose of 2.5 mg/kg bodyweight in cold allodynia test in rats with a Bennett ligation.


IT 409344-47-4P 409344-48-5P 409344-56-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinolines and quinolinones as metabotropic glutamate receptor antagonists)


RN 409344-47-4 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-(2-phenylacetyl)- (CA INDEX NAME)




RN 409344-48-5 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[2-(2-methoxyphenyl)acetyl]- (CA INDEX NAME)



RN 409344-56-5 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-(1-oxo-3-phenylpropyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:476381 CAPLUS
DOCUMENT NUMBER: 135:100164
TITLE: (R)-1-{(2-Oxo-1,2-dihydroquinolin-6-yl)[3-(trifluoromethyl)phenyl]methyl}-1H-1,2,4-triazol-4-ium bromide
AUTHOR(S): Peeters, Oswald M.; Blaton, Norbert M.; De Ranter, Camiel J.
CORPORATE SOURCE: Faculteit Farmaceutische Wetenschappen, Laboratorium voor Analytische Chemie en Medicinale Fysicochemie, Katholieke Universiteit Leuven, Louvain, B-3000, Belg.
SOURCE: Acta Crystallographica, Section E: Structure Reports Online (2001), E57(7), o655-o656
CODEN: ACSEBH; ISSN: 1600-5368
URL: <http://journals.iucr.org/e/issues/2001/07/00/ya6033.pdf>

PUBLISHER: International Union of Crystallography
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English
AB The metabolism of all-trans-retinoic acid is mediated by a cytochrome dependent P 450 system. The title compound, C₁₉H₁₄F₃N₄O₂·Br⁻ (R111214), is an inhibitor of P 450. The three planar ring systems, viz. the triazolyl, Ph and quinolinone groups, are arranged in a propeller-like fashion around the central CH group. The dihedral angles formed by the triazolyl/phenyl, triazolyl/quinolinone and phenyl/quinolinone planes are 55.8(1), 79.85(9) and 78.49(9)°, resp. The N-H...O H bonds, involving the triazolium N-H group and the quinolinone O atom, link the cations into infinite chains stretching along the c axis of the crystal. Crystallog. data are given.

IT 349553-99-7
RL: PRP (Properties)
(crystal structure of)
RN 349553-99-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[{(R)-1H-1,2,4-triazol-1-yl[4-(trifluoromethyl)phenyl]methyl}-, hydrobromide (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HBr


REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2001:223060 CAPLUS
 DOCUMENT NUMBER: 135:5590
 TITLE: Some nucleophilic reactions with 6-benzoyl-2,3-dichloroquinoxaline: synthesis of tetrazolo[1,5-a]quinoxoline, 2-methylidene-1,3-dithiolo[4,5-b]quinoxalines, quinoxalino[2,3-b]quinoxalines and pyrazolo[1',5':1,2]imidazolo[4,5-b]-quinoxalines
 AUTHOR(S): El-Gaby, M. S. A.; El-Sharief, A. M. Sh; Ammar, Y. A.; Mohamed, Y. A.; El-Salam, A. A. Abd
 CORPORATE SOURCE: Department of Chemistry, Faculty of Science, Al-Azhar University at Assiut, Assiut, 71524, Egypt
 SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2001), 40B(3), 195-200
 CODEN: IJSSDB; ISSN: 0376-4699
 PUBLISHER: National Institute of Science Communication, CSIR
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:5590
 AB The starting material 6-benzoyl-2,3-dichloroquinoxaline is subjected to some nucleophilic reagents to study the effect of the benzoyl group on the reactivity of the two chlorine atoms.
 IT 143702-68-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactions of 6-benzoyl-2,3-dichloroquinoxaline with nucleophiles)
 RN 143702-68-5 CAPLUS
 CN 2,3-Quinoxalinedione, 6-benzoyl-1,4-dihydro- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
 (5 CITINGS)
 REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2000:527827 CAPLUS
 DOCUMENT NUMBER: 134:162992
 TITLE: Synthesis and antimicrobial activities of some novel quinoxalinone derivatives
 AUTHOR(S): Ali, M. M.; Ismail, M. M. F.; El-Gaby, M. S. A.; Zahran, M. A.; Ammar, Y. A.
 CORPORATE SOURCE: Dep. of Chemistry, Faculty of Science, Al-Azhar Univ., Cairo, 11884, Egypt
 SOURCE: Molecules [online computer file] (2000), 5(6), 864-873
 CODEN: MOLEFW; ISSN: 1420-3049
 URL: <http://www.mdpi.org/molecules/papers/50600864.pdf>
 PUBLISHER: Molecular Diversity Preservation International
 DOCUMENT TYPE: Journal; (online computer file)
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 134:162992
 GI



AB Condensation of 4-benzoyl-1,2-phenylenediamine with sodium pyruvate in acetic acid furnished two products, which were identified as 6-benzoyl-(I) and 7-benzoyl-3-methyl-2(1H)-quinoxalinone (II). Fusion of I with aromatic aldehydes furnished the styryl derivs. Alkylation of I and II with di-Me sulfate or Et chloroacetate produced the N-alkyl derivs. Hydrazinolysis of one ester derivative with hydrazine hydrate afforded the hydrazone derivative, which underwent condensation with aldehydes to give the corresponding hydrazone derivs. In addition, chlorination of I with thionyl chloride afforded the 2-chloro derivative, which was subjected to reaction with sodium azide and n-butylamine to yield the corresponding tetrazole (III) and n-butylamino (IV) derivs., resp. The structures of the compds. prepared were confirmed by anal. and spectral data. Also, some of the synthesized compds. were screened for antimicrobial activity.


IT 325469-51-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation and antimicrobial activities of quinoxalinone derivs.)

RN 325469-51-0 CAPLUS
CN 2(1H)-Quinoxalinone, 6-benzoyl-3-methyl- (CA INDEX NAME)




IT 325469-54-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antimicrobial activities of quinoxalinone derivs.)
RN 325469-54-3 CAPLUS
CN 2(1H)-Quinoxalinone, 6-benzoyl-3-[(1E)-2-(4-methoxyphenyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




IT 325469-53-2P 325469-55-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antimicrobial activities of quinoxalinone derivs.)
RN 325469-53-2 CAPLUS
CN 2(1H)-Quinoxalinone, 6-benzoyl-3-[(1E)-2-(4-chlorophenyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 325469-55-4 CAPLUS
CN 2(1H)-Quinoxalinone, 6-benzoyl-3-[(1E)-2-(3,4,5-trimethoxyphenyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




OS.CITING REF COUNT: 41 THERE ARE 41 CAPLUS RECORDS THAT CITE THIS RECORD (41 CITINGS)
 REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1998:672545 CAPLUS
 DOCUMENT NUMBER: 129:275932
 ORIGINAL REFERENCE NO.: 129:56265a,56268a
 TITLE: Preparation of 3-oxadiazolylquinoxaline derivatives having affinity to benzodiazepine receptor
 INVENTOR(S): Ohno, Kazunori; Odai, Osamu; Furukawa, Kiyoshi; Oka, Makoto
 PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|--------------------------------|----------------------------------|
| WO 9842701 | A1 | 19981001 | WO 1998-JP827 | 19980227 <-- |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA,
UG, US, UZ, VN, YU, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| JP 2002241379 | A | 20020828 | JP 1997-87646 | 19970321 <-- |
| AU 9861179 | A | 19981020 | AU 1998-61179 | 19980227 <-- |
| PRIORITY APPLN. INFO.: | | | JP 1997-87646
WO 1998-JP827 | A 19970321 <--
W 19980227 <-- |

OTHER SOURCE(S): MARPAT 129:275932
 GI




AB Novel 3-oxadiazolylquinoxaline derivs. represented by general formula (I; wherein Het is oxadiazolyl; R1 is hydrogen, lower alkyl, trifluoromethyl, lower cycloalkyl, lower alkenyl, lower alkynyl, optionally substituted aryl, optionally substituted heteroaryl, or lower alkoxy; R2 is hydrogen, lower alkyl, trifluoromethyl, lower cycloalkyl, halogeno, hydroxy, lower alkoxy, cyano, nitro, acyl, optionally substituted benzoyl, amino, lower mono- or dialkylamino, lower alkoxy carbonylmethoxy, lower mono- or dialkylaminocarbonylmethoxy, or optionally substituted benzoyloxy; and R3 is hydrogen, lower alkyl, lower cycloalkyl, halogeno, or lower alkoxy), which are useful as a medicine, in particular, which have a selective affinity for benzodiazepine receptors and are useful as a brain activator and a remedy for senile dementia and Alzheimer's disease. Thus, a solution of 1,2-dihydro-2-oxo-3-quinoxaliniccarboxylic acid and N,N'-carbonyl diimidazole in DMF was heated with stirring for 3 h at 60°, followed by adding acetamidoxime, and the stirring was continued for another 1.5 h to give 52.6% the title compound (II; R1 = Me; R2 = H). The latter compound and I (R1 = Et, R2 = OMe) inhibited the binding of [³H]diazepam to synaptosome membrane fraction prepared from rat brain with IC₅₀ of 11.5 and 1.41 nM, resp.

IT 213743-73-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxadiazolylquinoxaline derivs. having affinity to benzodiazepine receptor as brain activators and remedies for senile dementia and Alzheimer's disease)

RN 213743-73-8 CAPLUS

CN 2(1H)-Quinoxalinone, 6-benzoyl-3-(3-ethyl-1,2,4-oxadiazol-5-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 **THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)**

REFERENCE COUNT: 9 **THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT**

L7 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1998:210752 CAPLUS

DOCUMENT NUMBER: 128:257445

ORIGINAL REFERENCE NO.: 128:50967a,50970a

TITLE: Preparation of indolylbenzoquinolinones and related compounds as protein kinase C inhibitors.

INVENTOR(S): Bergstrand, Hakan; Karabelas, Kostas; Sjo, Peter
 PATENT ASSIGNEE(S): Astra Aktiebolag (Publ), Swed.
 SOURCE: PCT Int. Appl., 63 pp.
 CODEN: PIXXD2


DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|-----------------|
| WO 9813368 | A1 | 19980402 | WO 1997-SE1582 | 19970919 <-- |
| W: AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| IN 1997DE02638 | A | 20050311 | IN 1997-DE2638 | 19970916 <-- |
| TW 472045 | B | 20020111 | TW 1997-86113549 | 19970918 <-- |
| ZA 9708469 | A | 19980325 | ZA 1997-8469 | 19970919 <-- |
| CA 2265854 | A1 | 19980402 | CA 1997-2265854 | 19970919 <-- |
| AU 9744775 | A | 19980417 | AU 1997-44775 | 19970919 <-- |
| AU 716279 | B2 | 20000224 | | |
| EP 929551 | A1 | 19990721 | EP 1997-943259 | 19970919 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| NZ 334531 | A | 20000929 | NZ 1997-334531 | 19970919 <-- |
| US 6271231 | B1 | 20010807 | US 1997-981266 | 19971218 <-- |
| US 20010025043 | A1 | 20010927 | US 2001-865231 | 20010525 <-- |
| PRIORITY APPLN. INFO.: | | | SE 1996-3505 | A 19960925 <-- |
| | | | SE 1997-2747 | A 19970718 <-- |
| | | | WO 1997-SE1582 | W 19970919 <-- |
| | | | US 1997-981266 | A3 19971218 <-- |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 128:257445

GI




AB Title compds. [I; A, X, Y, Z = C, N; ≥2 of A, X, Y, Z = C; may be substituted and/or annulated; excluding 3-(1H-indol-3-yl)-1H-quinoxalin-2-one, 3-(2-methyl-1H-indol-3-yl)-1H-quinoxalin-2-one, and 3-(1,2-diphenyl-1H-indol-3-yl)-1H-quinoxalin-2-one], were prepared as protein kinase C inhibitors (no data). Thus, 1,2-phenylenediamine was stirred overnight with [1-[3-(1,3-dioxoisooindol-2-yl)propyl]-1H-indol-3-yl]oxoacetic acid 2,5-dioxopyrrolidin-1-yl ester (preparation given) in THF to give 3-[3-(3-oxo-3,4-dihydroquinoxalin-2-yl)indol-1-yl]propylammonium

acetate. The latter was stirred with MeNH₂ in THF/H₂O to give
3-[3-(3-oxo-3,4-dihydroquinoxalin-2-yl)indol-1-yl]propylammonium acetate.
IT 205377-77-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolylbenzoquinoxalinones and related compds. as protein kinase C inhibitors)
RN 205377-77-1 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[1-(3-aminopropyl)-1H-indol-3-yl]-6-(phenylmethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 205377-76-0

CMF C26 H₂₄ N₄ O



CM 2

CRN 76-05-1

CMF C₂ H F₃ O₂




OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1996:527663 CAPLUS
DOCUMENT NUMBER: 125:167994
ORIGINAL REFERENCE NO.: 125:31485a,31488a
TITLE: Preparation of 6-[triazolyl(3-trifluoromethylphenyl)methyl]-2-quinolin(thi)ones for treatment of keratinization disorders
INVENTOR(S): Venet, Marc Gaston; Mabire, Dominique Jean-Pierre; Sanz, Gerard Charles
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------------|
| WO 9620200 | A1 | 19960704 | WO 1995-EP5173 | 19951221 <-- |
| W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN | | | | |
| RW: KE, LS, MM, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| IN 1995CA01685 | A | 20050304 | IN 1995-CA1685 | 19951220 <-- |
| CA 2207268 | A1 | 19960704 | CA 1995-2207268 | 19951221 <-- |
| AU 9644362 | A | 19960719 | AU 1996-44362 | 19951221 <-- |
| AU 698199 | B2 | 19981029 | | |
| EP 800524 | A1 | 19971015 | EP 1995-943237 | 19951221 <-- |
| EP 800524 | B1 | 20011031 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE | | | | |
| CN 1171789 | A | 19980128 | CN 1995-197162 | 19951221 <-- |
| CN 1085668 | C | 20020529 | | |
| JP 10511654 | T | 19981110 | JP 1995-520222 | 19951221 <-- |
| BR 9510504 | A | 19990601 | BR 1995-10504 | 19951221 <-- |
| RU 2165419 | C2 | 20010420 | RU 1997-112898 | 19951221 <-- |
| AT 207924 | T | 20011115 | AT 1995-943237 | 19951221 <-- |
| PT 800524 | E | 20020429 | PT 1995-943237 | 19951221 <-- |
| ES 2166838 | T3 | 20020501 | ES 1995-943237 | 19951221 <-- |
| PL 182956 | B1 | 20020531 | PL 1995-321041 | 19951221 <-- |
| ZA 9510989 | A | 19970627 | ZA 1995-10989 | 19951227 <-- |
| IL 116577 | A | 20000229 | IL 1995-116577 | 19951227 <-- |
| US 5922734 | A | 19990713 | US 1997-860239 | 19970616 <-- |
| FI 9702794 | A | 19970627 | FI 1997-2794 | 19970627 <-- |
| NO 9703029 | A | 19970627 | NO 1997-3029 | 19970627 <-- |
| NO 311220 | B1 | 20011029 | | |
| PRIORITY APPLN. INFO.: | | | EP 1994-203773 | A 19941228 <-- |
| | | | WO 1995-EP5173 | W 19951221 <-- |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 125:167994
GI

AB Title compds. [I; R = 3-(F3C)C6H4] [II; R1 = H, NH2, alkyl; R2,R3 = H, halo, alkyl; X = O or S; 1 of Z1,Z2 = N and the other = CH] were prepared Thus, (R)-II (R1-R3 = H, X = O, Z1 = N, Z2 = CH) gave complete suppression of estradiol undecylate-induced vaginal keratinization in 50% of ovariectomized rats at 1.25mg/kg orally.

| | | |
|-----------------|--------------|--------------|
| IT 180421-65-2P | 180421-66-3P | 180421-67-4P |
| 180421-68-5P | 180421-69-6P | 180421-70-9P |
| 180421-71-0P | 180421-72-1P | 180421-73-2P |
| 180421-74-3P | 180421-75-4P | |


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 6-[triazolyl(3-trifluoromethylphenyl)methyl]-2-quinolin(thi)ones for treatment of keratinization disorders)

RN 180421-65-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 180421-66-3 CAPLUS


CN 2(1H)-Quinolinone, 6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 180421-67-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 180421-68-5 CAPLUS


CN 2(1H)-Quinolinone, 6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 180421-69-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[fluoro-1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 180421-70-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)




RN 180421-71-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-methyl-1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)




RN 180421-72-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]pentyl]- (CA INDEX NAME)




RN 180421-73-2 CAPLUS
CN 2(1H)-Quinolinone, 8-methyl-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 180421-74-3 CAPLUS
CN 2(1H)-Quinolinone, 5-chloro-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 180421-75-4 CAPLUS
CN 2(1H)-Quinolinone, 8-fluoro-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1992:592207 CAPLUS
 DOCUMENT NUMBER: 117:192207
 ORIGINAL REFERENCE NO.: 117:33223a,33226a
 TITLE: Fluorine-19 NMR studies on the mechanism of riboflavin synthase. Synthesis of 6-(trifluoromethyl)-7-oxo-8-(D-ribityl)lumazine and 6-(trifluoromethyl)-7-methyl-8-(D-ribityl)lumazine
 AUTHOR(S): Cushman, Mark; Patel, Hemantkumar H.; Scheuring, Johannes; Bacher, Adelbert
 CORPORATE SOURCE: Sch. Pharm. Pharm. Sci., Purdue Univ., West Lafayette, IN, 47907, USA
 SOURCE: Journal of Organic Chemistry (1992), 57(21), 5630-43
 DOCUMENT TYPE: CODEN: JOCEAH; ISSN: 0022-3263
 LANGUAGE: English
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title oxo-(D-ribityl)lumazine I was synthesized by reaction of Me trifluoropyruvate with 5-amino-6-(D-ribitylamino)pyrimidine-2,4(1H,3H)-dione hydrochloride and utilized as a 19F NMR probe of the light riboflavin synthase of *Bacillus subtilis*. I was found to be an inhibitor of riboflavin synthase with an inhibition constant $K_I = 55 \mu\text{M}$. The enzyme-bound ligand gave rise to several broad 19F NMR signals which were shifted to low field. The bound ligand I could be displaced from the enzyme by the enzyme product, riboflavin (II), and the product analog, 5-nitroso-6-(ribitylamino)-2,4(1H,3H)-pyrimidinedione. Title methyl-(D-ribityl)lumazine III was synthesized by reaction of 5-amino-6-(D-ribitylamino)pyrimidine-2,4(1H,3H)-dione hydrochloride with 1,1,1-trifluorobutane-2,3-dione. Three mols. of III can be bound relatively tightly per mol of riboflavin synthase, i.e., one ligand mol. per protein subunit. A scheme for the catalytic cycle of riboflavin synthase is proposed.

IT 143309-79-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 143309-79-9 CAPLUS





CN 2(1H)-Quinoxalinone, 6-benzoyl-3-(trifluoromethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 33 THERE ARE 33 CAPLUS RECORDS THAT CITE THIS RECORD (33 CITINGS)

L7 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1992:571381 CAPLUS
 DOCUMENT NUMBER: 117:171381
 ORIGINAL REFERENCE NO.: 117:29633a,29636a

TITLE: Synthesis of pyrido[1',2':1,2]imidazo[4,5-b]quinoxalines
 AUTHOR(S): Tanaka, Kiyoshi; Takahashi, Hideki; Takimoto, Kozo;
 CORPORATE SOURCE: Sugita, Masahiko; Mitsuhashi, Keiryo
 SOURCE: Fac. Eng., Seikei Univ., Musashino, 180, Japan
 Journal of Heterocyclic Chemistry (1992),
 29(4), 771-7
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 117:171381
 GI




AB Synthesis of title compds. I ($R = H$, 8-, 9-Cl, 8-, 9-Bz, 8-, 9-NO₂; R1 = H, 1-, 2-, 3-, 4-Me, 4-PhCH₂O) by the facile cyclizations of 2,3-dichloroquinoxalines II with 2-aminopyridines III and of 2-amino-3-chloroquinoxalines IV ($R \neq H$) with various substituted pyridines is described.

IT 143702-68-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(chlorination of)

RN 143702-68-5 CAPLUS

CN 2,3-Quinoxalinedione, 6-benzoyl-1,4-dihydro- (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)

L7 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1990:612014 CAPLUS
 DOCUMENT NUMBER: 113:212014
 ORIGINAL REFERENCE NO.: 113:35835a, 35838a
 TITLE: Preparation of (1H-azol-1-ylmethyl)quinolines,
 -quinazolines, and -quinoxalines as drugs
 Freyne, Eddy Jean Edgard; Venet, Marc Gaston;
 Raeymaekers, Alfons Herman Margaretha; Sanz, Gerard
 Charles
 INVENTOR(S):
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
 SOURCE: Eur. Pat. Appl., 106 pp.
 CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------------|---|----------|-----------------|-----------------|
| EP 371564 | A2 | 19900606 | EP 1989-203014 | 19891128 <-- |
| EP 371564 | A3 | 19910529 | | |
| EP 371564 | B1 | 19950712 | | |
| R: AT, BE, CH,
US 5028606 | DE, ES, FR, GB, GR, IT, LI, LU, NL, SE
A | 19910702 | US 1989-434957 | 19891113 <-- |
| US 5037829 | A | 19910806 | US 1989-435120 | 19891113 <-- |
| CA 2002864 | A1 | 19900529 | CA 1989-2002864 | 19891114 <-- |
| CA 2002864 | C | 19991116 | | |
| DK 8905994 | A | 19900530 | DK 1989-5994 | 19891128 <-- |
| DK 172748 | B1 | 19990628 | | |
| NO 8904734 | A | 19900530 | NO 1989-4734 | 19891128 <-- |
| NO 174509 | B | 19940207 | | |
| NO 174509 | C | 19940518 | | |
| AU 8945646 | A | 19900607 | AU 1989-45646 | 19891128 <-- |
| AU 620946 | B2 | 19920227 | | |
| HU 52498 | A2 | 19900728 | HU 1989-6220 | 19891128 <-- |
| HU 205106 | B | 19920330 | | |
| ZA 8909076 | A | 19910731 | ZA 1989-9076 | 19891128 <-- |
| SU 1780536 | A3 | 19921207 | SU 1989-4742543 | 19891128 <-- |
| IL 92486 | A | 19930708 | IL 1989-92486 | 19891128 <-- |
| ES 2088889 | T3 | 19961001 | ES 1989-203014 | 19891128 <-- |
| FI 101964 | B | 19980930 | FI 1989-5687 | 19891128 <-- |
| FI 101964 | B1 | 19980930 | | |
| CA 1042912 | A | 19900613 | CN 1989-108925 | 19891129 <-- |
| CN 1033752 | C | 19970108 | | |
| JP 02223579 | A | 19900905 | JP 1989-307793 | 19891129 <-- |
| JP 2916181 | B2 | 19990705 | | |
| US 5151421 | A | 19920929 | US 1991-672298 | 19910320 <-- |
| US 5185346 | A | 19930209 | US 1991-704746 | 19910523 <-- |
| US 5268380 | A | 19931207 | US 1992-973871 | 19921110 <-- |
| US 5441954 | A | 19950815 | US 1993-131817 | 19931005 <-- |
| CN 1106004 | A | 19950802 | CN 1994-117801 | 19941102 <-- |
| CN 1036002 | C | 19971001 | | |
| CN 1106005 | A | 19950802 | CN 1994-117802 | 19941102 <-- |
| CN 1036003 | C | 19971001 | | |
| US 5612354 | A | 19970318 | US 1995-409551 | 19950323 <-- |
| PRIORITY APPLN. INFO.: | | | GB 1988-27820 | A 19881129 <-- |
| | | | GB 1988-27821 | A 19881129 <-- |
| | | | GB 1988-27822 | A 19881129 <-- |
| | | | US 1989-434205 | B2 19891113 <-- |
| | | | US 1989-434957 | A3 19891113 <-- |
| | | | US 1991-704746 | A3 19910523 <-- |
| | | | US 1992-973871 | A3 19921110 <-- |
| | | | US 1993-131817 | A3 19931005 <-- |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 113:212014

GI For diagram(s), see printed CA Issue.

AB The title compds. (I; R = H, alkyl; X1:X2 = CH:CH, CH:N, N:CH; Y = H, alkyl, cycloalkyl, alkenyl, alkynyl, (un)substituted aryl, aralkyl; Z = (un)substituted (oxo)quinolinyl, (oxo- or thioxo)quinazolinyl, (oxo- or dioxo)quinoxalinyl) were prepared as retinoic acid metabolism inhibitors, aromatase inhibitors, etc. Thus, 3,4-dihydroquinolin-2(1H)-one was stirred 2 h at 70° with BzCl in DMF containing AlCl3 and the product reduced by NaBH4 to give hydroxymethylquinolinone II (R1 = Ph, R2 = OH). II (R1 = Me, R2 = OH) was stirred overnight with SOCl2 in THF and the

product II (R1 = Me, R2 = Cl) stirred overnight at 60–70° with 1H-imidazole in DMSO to give II (R1 = Me, R2 = imidazolo) which maintained plasma levels of i.v. administered all-trans-retinoic acid at ≥10 ng/mL in rats 2 h after oral administration of 40 mg/kg.


| | | | |
|----|--------------|--------------|--------------|
| IT | 120067-41-6P | 130344-00-2P | 130344-01-3P |
| | 130344-02-4P | 130344-03-5P | 130346-18-8P |
| | 130346-22-4P | 130346-25-7P | 130346-26-8P |
| | 130346-27-9P | 130346-30-4P | 130346-42-8P |
| | 130346-51-9P | 130346-66-6P | 130346-68-8P |
| | 130346-69-9P | 130347-21-6P | 130347-22-7P |
| | 130347-23-8P | 130347-25-0P | 130347-26-1P |
| | 130347-28-3P | 130347-30-7P | 130347-31-8P |
| | 130347-33-0P | 130347-35-2P | 130347-37-4P |
| | 130347-39-6P | 130347-41-0P | 130347-42-1P |
| | 130347-44-3P | 130347-45-4P | 130347-46-5P |
| | 130347-47-6P | 130347-48-7P | 130347-62-5P |

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as retinol metabolism and aromatase inhibitor)


RN 120067-41-6 CAPLUS

CN 2(1H)-Quinolinone, 6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)




RN 130344-00-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 130344-01-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 130344-02-4 CAPLUS


CN 2(1H)-Quinolinone, 6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 130344-03-5 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 130346-18-8 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(1H-imidazol-1-ylphenylmethyl)-3-methyl- (CA INDEX NAME)




RN 130346-22-4 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(1H-imidazol-1-yl[3-(trifluoromethyl)phenyl]methyl]-3-methyl- (CA INDEX NAME)




RN 130346-25-7 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(2-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)




RN 130346-26-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-
(CA INDEX NAME)




RN 130346-27-9 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-
(CA INDEX NAME)




RN 130346-30-4 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-
(CA INDEX NAME)




RN 130346-42-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)




RN 130346-51-9 CAPLUS
CN 2(1H)-Quinoxalinone, 6-(1H-imidazol-1-ylphenylmethyl)-3-phenyl- (CA INDEX NAME)




RN 130346-66-6 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[4-chlorophenyl]-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)




RN 130346-68-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[1H-imidazol-1-yl(4-methoxyphenyl)methyl]-3-methyl- (CA INDEX NAME)




RN 130346-69-9 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)




RN 130347-21-6 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl-, 4-oxide (CA INDEX NAME)




RN 130347-22-7 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl- (CA INDEX NAME)




RN 130347-23-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(1H-imidazol-1-yl[4-(1-methylethyl)phenyl]methyl)-3-methyl- (CA INDEX NAME)




RN 130347-25-0 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-, 4-oxide (CA INDEX NAME)




RN 130347-26-1 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 130347-28-3 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 130347-30-7 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-propyl- (CA INDEX NAME)




RN 130347-31-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-methylethyl)- (CA INDEX NAME)




RN 130347-33-0 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130347-35-2 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl-, 4-oxide (CA INDEX NAME)




RN 130347-37-4 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-propyl- (CA INDEX NAME)




RN 130347-39-6 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-methylpropyl)- (CA INDEX NAME)




RN 130347-41-0 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-methylethyl)- (CA INDEX NAME)




RN 130347-42-1 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl- (CA INDEX NAME)




RN 130347-44-3 CAPLUS

CN 2(1H)-Quinoxalinone, 3-benzoyl-6-(1H-imidazol-1-ylphenylmethyl)-, 4-oxide (CA INDEX NAME)




RN 130347-45-4 CAPLUS


CN 2(1H)-Quinoxalinone, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA
INDEX NAME)




RN 130347-46-5 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(2-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA
INDEX NAME)



RN 130347-47-6 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA
INDEX NAME)




RN 130347-48-7 CAPLUS
CN 2(1H)-Quinoxalinone, 3-phenyl-6-(phenyl-1H-1,2,4-triazol-1-ylmethyl)- (CA
INDEX NAME)



RN 130347-62-5 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3,4-dichlorophenyl)-1H-imidazol-1-ylmethyl]-3-

phenyl- (CA INDEX NAME)




OS.CITING REF COUNT: 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (43 CITINGS)

L7 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1989:407401 CAPLUS
DOCUMENT NUMBER: 111:7401
ORIGINAL REFERENCE NO.: 111:1422h,1423a
TITLE: Imidazole- or pyridine-containing carbostyryls as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors, their preparation, and pharmaceuticals containing them
INVENTOR(S): Walker, Keith A. M.; Bruno, John J.; Martinez, Gregory R.
PATENT ASSIGNEE(S): Syntex (U.S.A.), Inc., USA
SOURCE: U.S., 20 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|----------|-----------------|--------------|
| US 4792561 | A | 19881220 | US 1986-868845 | 19860529 <-- |
| US 4921862 | A | 19900501 | US 1988-247134 | 19880921 <-- |

PRIORITY APPLN. INFO.: US 1986-868845 A3 19860529 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 111:7401; MARPAT 111:7401
GI



AB Title compds. I [X = R₁CR₂, cis- or trans-CR₃:CR₄; R₁ = H when R₂ = OH, or R₁ = Ph, phenylalkyl when R₂ = H, OH; Ph is optionally monosubstituted; or R₁R₂ = O, C₁-6 alkylidene, (substituted) benzylidene; R₃ = H, C₁-6 alkyl; R₄ = H; R₃R₄ = bond; n = 0-3; R = 1-imidazolyl; dotted line = optional covalent bond] are prepared as thromboxane synthetase and cAMP phosphodiesterase inhibitors for treatment of disease characterized by elevated thromboxane levels or an imbalance of prostacyclin/thromboxane levels (no data). A mixture of CuI 11.6, (Ph₃P)₂PdCl₂ 86,

N-propargylimidazole (preparation given) 774 mg, and 6-kromo-3,4-dihydrocarbostyryl 1.5 g was stirred in 10mL pyridine and 2 mL triethylamine at 100° for 48 h under N₂. The reaction mixture was then treated with saturated aqueous K₂CO₃, extracted with 10% MeOH in CH₂Cl₂, and


worked up to give 6-[3-(imidazol-1-yl)-1-propyn-1-yl]-3,4-dihydrocarbostyryl. The latter (502 mg) was stirred under H₂ in the presence of 200 mg 10% Pd/C to give 6-[3-(imidazol-1-yl)propyl]-3,4-dihydrocarbostyryl (II). A tablet was formulated containing II 25, cornstarch 20, spray-dried lactose 153, and Mg stearate 2 mg.

IT 120067-41-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as cAMP phosphodiesterase and thromboxane synthetase inhibitors)

RN 120067-41-6 CAPLUS

CN 2(1H)-Quinolinone, 6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

| | | | |
|--|--------|------------|---------|
| => fil stnguide | | | |
| COST IN U.S. DOLLARS | | SINCE FILE | TOTAL |
| FULL ESTIMATED COST | | ENTRY | SESSION |
| | 92.77 | | 478.03 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | | SINCE FILE | TOTAL |
| CA SUBSCRIBER PRICE | | ENTRY | SESSION |
| | -12.75 | | -12.75 |

FILE 'STNGUIDE' ENTERED AT 10:30:36 ON 29 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 26, 2010 (20100326/UP).

| | | | |
|--|------|------------|---------|
| => logoff | | | |
| ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF | | | |
| LOGOFF? (Y)/N/HOLD:y | | | |
| COST IN U.S. DOLLARS | | SINCE FILE | TOTAL |
| FULL ESTIMATED COST | | ENTRY | SESSION |
| | 1.05 | | 479.08 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | | SINCE FILE | TOTAL |
| CA SUBSCRIBER PRICE | | ENTRY | SESSION |
| | 0.00 | | -12.75 |

STN INTERNATIONAL LOGOFF AT 10:39:22 ON 29 MAR 2010